Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.41 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26673710 | 1.00 | CAMK2D (0.46) | CAMK2DAAK1NR1D1SMN1; SMN2HDAC10 | |
| SCHEMBL26673713 | 0.84 | NR1D1 (0.61) | AAK1NR1D1 | |
| SCHEMBL30592458 | 0.82 | NR1D1 (0.42) | CAMK2DAAK1NR1D1 | |
| SCHEMBL26673721 | 0.82 | NR1D1 (0.42) | CAMK2DAAK1NR1D1 | |
| SCHEMBL24144137 | 0.79 | NR1D1 (0.46) | NR1D1SMN1; SMN2GAACNR2CNR1 | |
| SCHEMBL21614209 | 0.78 | MTNR1A (0.53) | CAMK2D | |
| SCHEMBL18918098 | 0.75 | CAMK2D (0.42) | CAMK2DSMN1; SMN2HDAC10HDAC6CNR2 | |
| SCHEMBL24144136 | 0.75 | CYP19A1 (0.44) | NR1D1SMN1; SMN2CNR2CNR1TBXA2R | |
| SCHEMBL24144934 | 0.74 | NR1D1 (0.42) | NR1D1SMN1; SMN2IDO1GAACNR2 | |
| SCHEMBL18926956 | 0.74 | DYRK1A (0.47) | CAMK2DHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | NR1H2, NR1H3, NR1D1 | CAMK2D 1414/4885AAK1 2696/4885NR1D1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.